Bio/Pharmaceutical Outsourcing Report, September 2026

All the vital news, analysis, and commentary curated by our industry experts.

$2950

Buy Report

Published: October 19, 2026 Report Code: GDPB093-ST

Report Overview
Key Players
Table of Contents
Table
Figures

The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.

Scope

This report gives an important monthly update on the pharmaceutical outsourcing industry, based on analysis from GlobalData's experts and our databases covering deals, companies, drugs, financials, news, clinical trials, and more. This report is required reading for:

– CMO executives and strategic decision-makers: to improve understanding of the CMO industry and provide a critical input for strategic planning efforts.

– Sourcing and procurement executives in bio/pharmaceutical companies: to improve understanding of crucial components of the supply base that will provide insights for supplier selection and management.

– Investors, advisors, and consultants: they can gain a deeper understanding of the CMO market and important insights for identifying potential investment targets.

Reasons to Buy

Understand current trends and equip yourself with forward-thinking strategies to navigate challenges and capitalise on emerging trends driving the pharmaceutical manufacturing industry. Use our radar to identify developments and innovations with high impact.

Discover the latest opportunities and threats in the contract manufacturing industry, based on clinical trials and regulatory decisions.

Learn about the past quarter’s M&A and financing deals in the manufacturing space.

Identify the latest contract service agreements.

Develop your competitor or market intelligence by reading about inspection outcomes and facility investments.

Stay ahead of disruption with updates on supply chain obstacles and new regulations.

4basebio Plc
A1 Biochem Labs India Private Limited
AbClon Inc
ABL Diagnostics
ABIONYX Pharma SA
Acadia Pharmaceuticals Inc
ACS Dobfar
Alcami Corp
ALK-Abello Ltd
Almac Group Ltd
American Type Culture Collection
Amylyx Pharmaceuticals Inc
Anaquant SAS
Ardian Holding
AstraZeneca
Astrea Pharma
AtomVie Global Radiopharma Inc
Aurobindo Pharma Limited
Axiom Biosciences
Bachem Americas Inc
Bayer HealthCare Pharmaceuticals Inc
BC Partners LLP
BeiGene USA Inc
Besins Healthcare SA
BioCina Pty Ltd
Biofrontera Inc
Bionova Scientific Inc
Biogen Inc
Bristol Myers Squibb (BMS)
Boehringer Ingelheim
Bright Path Laboratories Inc
BSP Pharmaceuticals SpA
Cambrex Corp
Can-Fite BioPharma Ltd
Cardinal Health
Catalent
Cellares Corp
Cellipont Bioservices
Cerbios Pharma SA
Chemspec-API Inc
Chime Biologics Ltd
Clean Cells SAS
Cook MyoSite
Corden Pharma International GmbH
Curia Global Inc
Curium
Dai Nippon Printing Co Ltd
Daiichi Sankyo
Delpharm SAS
Dottikon Exclusive Synthesis AG
ElevateBio LLC
Entropy Neurodynamics Ltd
EOC Pharma Ltd
Epilepsy GTX
Esteve Química SA
EUROAPI
Evonik Industries AG
Ferndale Pharma Group Inc
Flamma SpA
Freestyle Capital
Fritz Keller Holding AG
Fujifilm Diosynth Biotechnologies UK Ltd
Fujimoto Chemicals Co Ltd
Gaelic Laboratories
GBA Holding GmbH
GeneFab LLC
Genentech
Genezen Laboratories Inc
Genprex Inc
Gilead Sciences
GlobalData
GlaxoSmithKline (GSK)
HBM Holdings Ltd
Hovione FarmaCiencia SA
Huvepharma AD
Immutep Ltd
InfoRLife SA
Ingenza Ltd
Intertek Group Plc
Isotope Bidco Ltd
Isotope Technologies Munich (ITM)
IVERIC bio Inc
Janssen
Jazz Pharmaceuticals Inc
KC Pharmaceuticals Inc
Kincell Bio LLC
Kincellis Advanced Therapies
Kirin Holdings Co Ltd
Kyowa Hakko Bio Co Ltd
Kyowa Pharma Chemical Co Ltd
Lantheus
Lannett Co Inc
Leo Pharma
Lentigen Technology Inc
Lifeline Cell Technology LLC
Eli Lilly and Company
Lonza Group Ltd
MacroGenics Inc
Mabion SA
MCS Laboratories
Merck & Co
Minaris Advanced Therapies LLC
Moderna
Monrol
Neopharmed Gentili SpA
Niowave
Northway Biotech UAB
Northway Group
Novartis
Novavax Inc
Novo
Nucleis
Oak HC/FT Partners LLC
Onyx Scientific Ltd
Otsuka Pharmaceutical
Par Sterile Products LLC
Parabolic Drugs Ltd
Patheon
PCI Pharma Services
PharmaEssentia Corp
PharmaKorell GmbH
Pharming Healthcare
Inc
Pluristyx Inc
PolyPeptide Group AG
PPD
Prime Radiant Fund SLP SICAV-RAIF
Quoin Pharmaceuticals Ltd
Raghava Life Sciences Pvt Ltd
RayzeBio
Regeneron Pharmaceuticals Inc
ROVI Pharma Industrial Services
RPG Active Pharma Ltd
Samsung Biologics Co Ltd
Sharp Packaging Services LLC
SHS Capital
Siegfried Holding AG
Simtra US LLC
SK Bioscience Ltd
SK Pharmteco Inc
Skyepharma Production SAS
Spyre Therapeutics Inc
Suzhou Hillhouse Qirui Medical Health Industry Investment Partnership
Swift Ventures Management LLC
Telix Pharmaceuticals
TerraPower Isotopes
Texcell SA
Thermo Fisher Scientific
TopChem Pharmaceuticals Ltd
Uquifa SA
UniD Manufacturing SA
Vetter Pharma-Fertigung GmbH & Co KG
Vifor Pharma UK Ltd
ViiV Healthcare Company
Viral Vector Manufacturing Facility Pty Ltd
Viralgen Vector Core SL
WuXi AppTec
WuXi Advanced Therapies
WuXi Biologics
WuXi XDC Cayman Inc
Xiogenix Inc
Yuhan Chemical Inc

Table of Contents

1 Industry Trends

1.1 Radiopharmaceutical growth is outpacing manufacturing infrastructure

1.2 CPHI 2026: Finding the right CDMO partner in an age of consolidation

1.3 CPHI 2026: Moderna builds on its COVID-era manufacturing lessons

1.4 Gaelic Labs: The EU Critical Medicines Act will have a positive impact on supply

2 Industry Analysis

2.1 Contract service agreements

2.2 Contract manufacturing – opportunities and threats

2.3 Quarterly mergers, acquisitions, and financing – Q3 2026

3 Value Chain

3.1 API chemical

3.2 API biologics – cell, gene, vaccine, and virus

3.3 API biologics – protein and peptide

3.4 Commercial dose manufacturing and packaging

3.5 Analytical services

4 About GlobalData

5 About the Authors

6 Contact Us

Table

Table 1: Contract service agreements

Table 2: Contract manufacturing: opportunities and threats – potentially positive

Table 3: Contract manufacturing: opportunities and threats – potentially negative

Table 4: Mergers, acquisitions, and financing – Q3 2026

Figures

Figure 1: Contract service agreements by deal geography, by volume

Figure 2: Deals by deal geography, by volume – mergers, acquisitions, and financing

Figure 3: The contract manufacturing value chain

Bio/Pharmaceutical Outsourcing Report, September 2026 standard reports

Currency USD

Single User

$2,950

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Contract Manufacturers reports

Pharmaceuticals

New

Bio/Pharmaceutical Outsourcing Report, September 2026

Pharmaceuticals

New

IDWeek 2026: Pre-Conference Coverage

Pharmaceuticals

New

Gonorrhea: Market View, Current and Future Competitive Landscape

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bio/Pharmaceutical Outsourcing Report, September 2026 in real time.

Access a live Bio/Pharmaceutical Outsourcing Report, September 2026 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Bio/Pharmaceutical Outsourcing Report, September 2026

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports